{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:26:19Z","timestamp":1728361579138},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Clin Rheumatol"],"abstract":"\n Background\/Objective<\/jats:title>\n This study aims to evaluate ibandronate clinical effectiveness in the prevention of osteoporosis-related vertebral fractures (VFs) and nonvertebral fractures (NVFs) in the treatment of postmenopausal osteoporosis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This systematic review was conducted in accordance with the Centre for Reviews and Dissemination's guidance and reporting in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement 2020. A literature search was performed in PubMed and EMBASE since their inception until February 7, 2022. Randomized controlled trials (RCTs), meta-analysis, experimental, and observational studies evaluating adult patients treated with ibandronate and assessed to osteoporotic fractures prevention were included. The risk of bias was assessed according to study design. Data were analyzed using descriptive statistics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Eight references from 4 RCTs, 7 meta-analyses, and 6 observational studies were included. In RCTs, oral ibandronate was superior to placebo in the prevention of VF. However, the doses were lower than those approved. The meta-analyses confirmed these results and showed that adequate doses of oral ibandronate reduce the risk of NVF compared with insufficient doses. In observational studies, oral ibandronate (in approved doses) reduced the risk of VF compared with no treatment or risedronate or alendronate and the risk of NVF versus risedronate or alendronate; the risk of hip fractures was similar between ibandronate and other oral bisphosphonates.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n There is strong evidence that ibandronate reduces the risk of VF in postmenopausal osteoporosis. The available evidence further suggests that ibandronate may reduce the risk of NVF versus insufficient doses of ibandronate, as well as risedronate or alendronate.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/rhu.0000000000001902","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T22:20:28Z","timestamp":1675376428000},"update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures"],"prefix":"10.1097","author":[{"given":"Diogo","family":"Mendes","sequence":"first","affiliation":[]},{"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Alves","sequence":"additional","affiliation":[]},{"given":"T\u00e2nia","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Tecnimede, SA, Sintra, Portugal."}]},{"given":"Ant\u00f3nio","family":"Donato","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Batel-Marques","sequence":"additional","affiliation":[]}],"member":"276","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"bib1-20241007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","article-title":"Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis","volume":"89","year":"2016","journal-title":"Bone"},{"key":"bib2-20241007","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","year":"2004","journal-title":"J Bone Miner Res"},{"key":"bib3-20241007","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","year":"2005","journal-title":"J Bone Miner Res"},{"key":"bib4-20241007","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study","volume":"65","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"bib5-20241007","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study","volume":"54","year":"2006","journal-title":"Arthritis Rheum"},{"key":"bib6-20241007","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","year":"2008","journal-title":"J Rheumatol"},{"key":"bib7-20241007","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"bib8-20241007","first-page":"29","article-title":"Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project","volume":"37","year":"2022","journal-title":"J Bone Miner Res"},{"key":"bib11-20241007","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00198-012-1935-8","article-title":"Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)","volume":"23","year":"2012","journal-title":"Osteoporos Int"},{"key":"bib12-20241007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","article-title":"Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies","volume":"24","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"bib13-20241007","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12891-019-2769-8","article-title":"Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials","volume":"20","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"bib15-20241007","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","year":"2021","journal-title":"BMJ"},{"key":"bib16-20241007","first-page":"j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","year":"2017","journal-title":"BMJ"},{"key":"bib17-20241007","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","year":"2019","journal-title":"BMJ"},{"key":"bib18-20241007","first-page":"i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","year":"2016","journal-title":"BMJ"},{"key":"bib19-20241007","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bone.2005.05.004","article-title":"Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis","volume":"37","year":"2005","journal-title":"Bone"},{"key":"bib20-20241007","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1185\/030079905X30752","article-title":"Ibandronate produces significant, similar antifracture efficacy in north American and European women: new clinical findings from BONE","volume":"21","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"bib21-20241007","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","year":"2004","journal-title":"Osteoporos Int"},{"key":"bib22-20241007","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1185\/03007990903512321","article-title":"Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA","volume":"26","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"bib23-20241007","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00774-015-0723-x","article-title":"Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study","volume":"35","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"bib24-20241007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","article-title":"Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg\/month intravenous ibandronate versus 2.5 mg\/day oral risedronate in patients with primary osteoporosis","volume":"93","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"bib25-20241007","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","year":"2004","journal-title":"Bone"},{"key":"bib26-20241007","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","year":"2016","journal-title":"Osteoporos Int"},{"key":"bib27-20241007","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"bib28-20241007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis","volume":"40","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"bib29-20241007","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1185\/03007990903035281","article-title":"Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies","volume":"25","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"bib30-20241007","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","article-title":"Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data","volume":"20","year":"2009","journal-title":"Osteoporos Int"},{"key":"bib31-20241007","first-page":"5517247","article-title":"The effects of trends in osteoporosis treatment on the incidence of fractures","volume":"2021","year":"2021","journal-title":"J Osteoporos"},{"key":"bib32-20241007","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00198-018-4778-0","article-title":"Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study","volume":"30","year":"2019","journal-title":"Osteoporos Int"},{"key":"bib33-20241007","first-page":"302","article-title":"Fractures and mortality in relation to different osteoporosis treatments","volume":"33","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"bib34-20241007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.189","article-title":"Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008","volume":"26","year":"2011","journal-title":"J Bone Miner Res"},{"key":"bib35-20241007","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00198-009-1046-3","article-title":"Longitudinal change in clinical fracture incidence after initiation of bisphosphonates","volume":"21","year":"2010","journal-title":"Osteoporos Int"},{"key":"bib36-20241007","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bone.2009.01.002","article-title":"Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate efficacy (VIBE) database fracture study","volume":"44","year":"2009","journal-title":"Bone"},{"key":"bib37-20241007","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"bib38-20241007","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group","volume":"85","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"bib39-20241007","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","year":"2004","journal-title":"Bone"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0000000000001902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T21:17:59Z","timestamp":1728335879000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0000000000001902"}},"subtitle":["A Systematic Review of Experimental and Observational Studies"],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1097\/rhu.0000000000001902","relation":{},"ISSN":["1536-7355","1076-1608"],"issn-type":[{"type":"electronic","value":"1536-7355"},{"type":"print","value":"1076-1608"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}